STOCK TITAN

Immuneering Corp - IMRX STOCK NEWS

Welcome to our dedicated news page for Immuneering (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immuneering's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immuneering's position in the market.

Rhea-AI Summary
Immuneering (IMRX) announces the dosing of the first patient in its Phase 1/2a trial of IMM-6-415 for advanced solid tumors with RAF or RAS mutations. IMM-6-415, a Deep Cyclic Inhibitor of the MAPK pathway, shows promising tumor growth inhibition in preclinical studies. Initial PK, PD, and safety data expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
clinical trial
-
Rhea-AI Summary
Immuneering Corporation (IMRX) announces positive topline results from Phase 1 trial of IMM-1-104 in advanced RAS-mutant solid tumors. The candidate shows well-tolerated safety profile, target lesion regression, and suppression of RAS alterations. Phase 2a study underway with promising initial data expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50.68%
Tags
clinical trial
-
Rhea-AI Summary
Immuneering Corporation (IMRX) appoints Thomas J. Schall, Ph.D., former Chairman, CEO, and Founder of ChemoCentryx, to its Board of Directors. Dr. Schall brings 25 years of experience in drug discovery and commercialization, with a focus on developing universal-RAS/RAF medicines for cancer patients. His appointment aims to enhance Immuneering's strategic objectives in advancing its pipeline of cancer medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
management
Rhea-AI Summary
Immuneering Corporation (IMRX) announces dosing of first patient with IMM-1-104 in combination therapy for pancreatic cancer. Phase 2a trial to evaluate IMM-1-104 in multiple cancers. Topline Phase 1 data expected in March 2024. Initial Phase 2a data anticipated in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
clinical trial
-
Rhea-AI Summary
Immuneering Corporation (IMRX) to present preclinical data on lead program IMM-1-104 at AACR annual meeting, focusing on RAS-altered pancreatic cancer models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences clinical trial
-
Rhea-AI Summary
Immuneering Corporation (IMRX) to participate in Cowen 44th Annual Health Care Conference to discuss pipeline and business strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Immuneering Corporation (IMRX) reported financial results for Q4 and full year 2023, with topline data from Phase 1/2a trials expected in March 2024. FDA Fast Track designation received for IMM-1-104 in pancreatic cancer. Cash runway extended into 2H 2025. The company raised $30 million in an offering and reported positive Phase 1 data for IMM-1-104.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
earnings
-
Rhea-AI Summary
Immuneering Corporation (IMRX) receives Fast Track designation from the FDA for its lead clinical-stage program IMM-1-104 for pancreatic ductal adenocarcinoma. The company anticipates multiple readouts from its Phase 1/2a clinical trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
clinical trial
-
Rhea-AI Summary
Immuneering Corporation (IMRX) will participate in two February investor conferences to discuss the company’s pipeline, platform, and business strategy. The company aims to develop universal-RAS/RAF medicines for broad cancer patient populations. Participating will be the CEO, CSO, CBO, and CAO, discussing the company's progress and future plans. The conferences include Guggenheim 6th Annual Biotechnology Conference and Oppenheimer 34th Annual Healthcare Life Sciences Conference, with live webcasts available on Immuneering’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
Rhea-AI Summary
Immuneering Corporation (IMRX) has received FDA clearance for its Investigational New Drug (IND) application for IMM-6-415, paving the way for a Phase 1/2a clinical trial for the treatment of advanced RAF or RAS mutant solid tumors. The company expects to dose the first patient in early 2024. IMM-6-415 is a deep cyclic inhibitor of the MAPK pathway with unique drug-like properties and has shown promising preclinical single-agent and combination anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
clinical trial
Immuneering Corp

Nasdaq:IMRX

IMRX Rankings

IMRX Stock Data

71.16M
15.62M
28.33%
52.14%
9.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge